Literature DB >> 29572710

Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis.

Irakoze Laurent1,2, Siying Tang1, Manirakiza Astère3, Kan Ran Wang1, Shuhua Deng1, Ling Xiao4, Qi Fu Li5.   

Abstract

PURPOSE: To compare the effectiveness of liquid L-T4 (L-thyroxine) and tablet L-T4 in patients on L-T4 replacement or suppressive therapy.
METHODS: The Cochrane Library, PubMed, Embase, and Web of Science databases were searched to identify relevant articles. All prospective or randomized controlled studies (RCTs) comparing liquid L-T4 and tablet L-T4 in patients on L-T4 replacement or suppressive therapy were included in the analysis.
RESULTS: Overall, the initial search of the four databases identified 1278 published studies; of these, eight studies were ultimately included in the meta-analysis. TSH (thyroid stimulating hormone) levels were significantly suppressed in patients on liquid L-T4 compared with those on tablet L-T4, in patients on L-T4 suppressive therapy with L-T4 malabsorption (Mean Difference (MD) = -2.26, 95% Confidence Interval (CI): -3.59, -0.93; P = 0.0009)). However, liquid L-T4 and tablet L-T4 did not show a statistically significant difference in patients on L-T4 suppressive therapy without malabsorption (MD = 0.08, 95% CI: -0.31, 0.47; P = 0.69). TSH levels were significantly normalized in patients on liquid L-T4 compared with those on tablet L-T4, in Patients on L-T4 replacement therapy with L-T4 malabsorption (MD = -3.20, 95% CI: -5.08, -1.32; P = 0.0009). However, liquid L-T4 and tablet L-T4 did not show a statistically significant difference in patients on L-T4 replacement therapy without malabsorption (MD = 0.91, 95% CI: -0.03, 1.86; P = 0.06).
CONCLUSION: Liquid L-T4 is more efficient than tablet L-T4 in patients on L-T4 replacement or suppressive therapy with malabsorption. No significant differences were observed in patients without malabsorption. Further studies should be conducted to verify these findings.

Entities:  

Keywords:  Hypothyroidism; Liquid L-thyroxine; Meta-analysis; Tablet L-thyroxine; Thyroid cancer

Mesh:

Substances:

Year:  2018        PMID: 29572710     DOI: 10.1007/s12020-018-1574-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  48 in total

1.  TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Stefania Camastra; Ugo Politti; Ilaria Ruffilli; Roberto Vita; Giuseppe Navarra; Salvatore Benvenga; Alessandro Antonelli
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

2.  Oral liquid levothyroxine treatment at breakfast: a mistake?

Authors:  Carlo Cappelli; Ilenia Pirola; Elena Gandossi; Annamaria Formenti; Maurizio Castellano
Journal:  Eur J Endocrinol       Date:  2013-11-22       Impact factor: 6.664

3.  Utility of a Liquid Formulation of Levo-thyroxine in Differentiated Thyroid Cancer Patients.

Authors:  M Giusti; L Mortara; N Machello; E Monti; G Pera; M Marenzana
Journal:  Drug Res (Stuttg)       Date:  2014-07-14

Review 4.  Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis.

Authors:  Xing-Shun Qi; Yong-Xin Bao; Ming Bai; Wen-Da Xu; Jun-Na Dai; Xiao-Zhong Guo
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

5.  Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Alessandro Antonelli
Journal:  Endocrine       Date:  2015-12-31       Impact factor: 3.633

Review 6.  Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.

Authors:  Loredana Bianchi; Luigi Rossi; Federica Tomao; Anselmo Papa; Federica Zoratto; Silverio Tomao
Journal:  Endocr Relat Cancer       Date:  2013-08-19       Impact factor: 5.678

7.  A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.

Authors:  Roberto Vita; Giovanna Saraceno; Francesco Trimarchi; Salvatore Benvenga
Journal:  Endocrine       Date:  2012-08-30       Impact factor: 3.633

8.  Multinodular goiter in children: treatment controversies.

Authors:  Emilio García-García; Mercedes López-González; Rosa Cabello-Laureano; Elena Navarro-González
Journal:  J Pediatr Endocrinol Metab       Date:  2017-08-28       Impact factor: 1.634

Review 9.  The administration of L-thyroxine as soft gel capsule or liquid solution.

Authors:  Roberto Vita; Poupak Fallahi; Alessandro Antonelli; Salvatore Benvenga
Journal:  Expert Opin Drug Deliv       Date:  2014-06-04       Impact factor: 6.648

Review 10.  [Thyroid dysfunction in patients treated with tyrosine kinase inhibitors].

Authors:  Justyna Przytulska; Krzysztof Tupikowski; Grazyna Bednarek-Tupikowska
Journal:  Pol Merkur Lekarski       Date:  2014-01
View more
  15 in total

Review 1.  Novel thyroxine formulations: a further step toward precision medicine.

Authors:  Camilla Virili; Pierpaolo Trimboli; Marco Centanni
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

2.  Topical L-thyroxine: The Cinderella among hormones waiting to dance on the floor of dermatological therapy?

Authors:  Ralf Paus; Yuval Ramot; Robert S Kirsner; Marjana Tomic-Canic
Journal:  Exp Dermatol       Date:  2020-08-28       Impact factor: 3.960

Review 3.  Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?

Authors:  Marco Castellana; Carlo Castellana; Luca Giovanella; Pierpaolo Trimboli
Journal:  Endocrine       Date:  2020-01-17       Impact factor: 3.633

4.  Metabolic Syndrome in Offspring of Parents with Metabolic Syndrome: A Meta-Analysis.

Authors:  Laurent Irakoze; Astère Manirakiza; Yunqi Zhang; Juncheng Liu; Jiayu Li; Liliane Nkengurutse; Shuhua Deng; Xiaoqiu Xiao
Journal:  Obes Facts       Date:  2021-01-28       Impact factor: 3.942

Review 5.  Hypothyroidism.

Authors:  Layal Chaker; Salman Razvi; Isabela M Bensenor; Fereidoun Azizi; Elizabeth N Pearce; Robin P Peeters
Journal:  Nat Rev Dis Primers       Date:  2022-05-19       Impact factor: 52.329

Review 6.  Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer.

Authors:  Ilaria Stramazzo; Silvia Capriello; Alessandro Antonelli; Poupak Fallahi; Marco Centanni; Camilla Virili
Journal:  Hormones (Athens)       Date:  2022-06-02       Impact factor: 2.885

Review 7.  Levothyroxine Therapy in Gastric Malabsorptive Disorders.

Authors:  Camilla Virili; Nunzia Brusca; Silvia Capriello; Marco Centanni
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-28       Impact factor: 5.555

Review 8.  L-T4 Therapy in Enteric Malabsorptive Disorders.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Alessandro Antonelli
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-23       Impact factor: 5.555

Review 9.  Managing symptoms in hypothyroid patients on adequate levothyroxine: a narrative review.

Authors:  Salman Razvi; Sanaa Mrabeti; Markus Luster
Journal:  Endocr Connect       Date:  2020-11       Impact factor: 3.335

Review 10.  Levothyroxine Interactions with Food and Dietary Supplements-A Systematic Review.

Authors:  Agnieszka Wiesner; Danuta Gajewska; Paweł Paśko
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.